{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:48:57Z","timestamp":1788922137275,"version":"build-2803163510"},"reference-count":49,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2024,7,19]],"date-time":"2024-07-19T00:00:00Z","timestamp":1721347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK069861"],"award-info":[{"award-number":["DK069861"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["DK079974"],"award-info":[{"award-number":["DK079974"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012301","name":"Einstein-Mount Sinai Diabetes Research Center","doi-asserted-by":"publisher","award":["5P30DK020541-41"],"award-info":[{"award-number":["5P30DK020541-41"]}],"id":[{"id":"10.13039\/100012301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science Einstein-Montefiore Clinical and Translational Science Awards","doi-asserted-by":"publisher","award":["UL1TR001073"],"award-info":[{"award-number":["UL1TR001073"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Science Einstein-Montefiore Clinical and Translational Science Awards","doi-asserted-by":"publisher","award":["UL1TR002556"],"award-info":[{"award-number":["UL1TR002556"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-18-PMF-024"],"award-info":[{"award-number":["1-18-PMF-024"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Hypoglycemia-associated autonomic failure (HAAF), defined as blunting of counterregulatory hormone and symptom responses to recurrent hypoglycemia, remains a therapeutic challenge in diabetes treatment. The opioid system may play a role in HAAF pathogenesis since activation of opioid receptors induces HAAF. Blockade of opioid receptors with intravenous naloxone ameliorates HAAF experimentally yet is not feasible therapeutically.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the effects of opioid receptor blockade with intranasal naloxone on experimentally induced HAAF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomized, double-blinded, placebo-controlled crossover study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Academic research center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Healthy nondiabetic volunteers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Paired 2-day studies, 5 to 10 weeks apart, each consisting of 3 consecutive hypoglycemic episodes (hyperinsulinemic hypoglycemic clamps, glucose nadir: 54 mg\/dL): 2 on day 1 with administration of intranasal naloxone vs placebo, followed by the third episode on day 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Differences in counterregulatory hormones responses and hypoglycemia symptoms between first and third hypoglycemic episodes in naloxone vs placebo studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Out of 17 participants, 9 developed HAAF, confirming variable interindividual susceptibility. Among participants susceptible to HAAF, naloxone maintained some hormonal and symptomatic responses to hypoglycemia and prevented the associated requirement for increased glucose infusion. Unexpectedly, naloxone reduced plasma epinephrine and GH responses to the first hypoglycemic episode but prevented further reduction with subsequent hypoglycemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This is the first study to report that intranasal naloxone, a widely used opioid receptor antagonist, may ameliorate some features of HAAF. Further investigation is warranted into mechanisms of variable interindividual susceptibility to HAAF and the effects of intranasal naloxone in people with diabetes at risk for HAAF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgae479","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T02:04:37Z","timestamp":1721268277000},"page":"462-470","source":"Crossref","is-referenced-by-count":6,"title":["Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9255-1392","authenticated-orcid":false,"given":"Sandra","family":"Aleksic","sequence":"first","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Lontchi-Yimagou","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Boyle","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Matias","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Manavalan","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akankasha","family":"Goyal","sequence":"additional","affiliation":[{"name":"New York University Langone Medical Center , New York, NY 10017 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Carey","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration , Silver Spring, MD 20903 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Gabriely","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-010X","authenticated-orcid":false,"given":"Meredith","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY 10461 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,7,19]]},"reference":[{"issue":"5","key":"2025012110264103500_dgae479-B1","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(18)30315-2","article-title":"Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"2025012110264103500_dgae479-B2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus","volume":"329","author":"The Diabetes Control and Complications Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"issue":"4","key":"2025012110264103500_dgae479-B3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.2337\/dc16-0985","article-title":"Trends in drug utilization, glycemic control, and rates of severe hypoglycemia, 2006\u20132013","volume":"40","author":"Lipska","year":"2017","journal-title":"Diabetes Care"},{"issue":"3","key":"2025012110264103500_dgae479-B4","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1136\/jim-2017-000582","article-title":"Potential approaches to prevent hypoglycemia-associated autonomic failure","volume":"66","author":"Lontchi-Yimagou","year":"2018","journal-title":"J Investig Med"},{"issue":"3","key":"2025012110264103500_dgae479-B5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1172\/JCI116302","article-title":"Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia","volume":"91","author":"Dagogo-Jack","year":"1993","journal-title":"J Clin Invest"},{"issue":"6","key":"2025012110264103500_dgae479-B6","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2337\/dc21-1957","article-title":"An atypical form of diabetes among individuals with low BMI","volume":"45","author":"Lontchi-Yimagou","year":"2022","journal-title":"Diabetes Care"},{"issue":"6","key":"2025012110264103500_dgae479-B7","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1210\/clinem\/dgac020","article-title":"New concepts in the pathogenesis of cystic fibrosis-related diabetes","volume":"107","author":"Moheet","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012110264103500_dgae479-B8","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.amjmed.2011.08.008","article-title":"Death during intensive glycemic therapy of diabetes: mechanisms and implications","volume":"124","author":"Cryer","year":"2011","journal-title":"Am J Med"},{"issue":"4","key":"2025012110264103500_dgae479-B9","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/1932296819831695","article-title":"Impact of CGM on the management of hypoglycemia problems: overview and secondary analysis of the HypoDE study","volume":"13","author":"Hermanns","year":"2019","journal-title":"J Diabetes Sci Technol"},{"issue":"6","key":"2025012110264103500_dgae479-B10","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1210\/jcem-49-6-838","article-title":"Substantial rise of plasma beta-endorphin levels after insulin-induced hypoglycemia in human subjects","volume":"49","author":"Nakao","year":"1979","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025012110264103500_dgae479-B11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0006-8993(88)90475-1","article-title":"Effects of insulin-induced hypoglycemia on plasma and cerebrospinal fluid levels of ir-beta-endorphins, ACTH, cortisol, norepinephrine, insulin and glucose in the conscious dog","volume":"458","author":"Radosevich","year":"1988","journal-title":"Brain Res"},{"issue":"11","key":"2025012110264103500_dgae479-B12","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.2337\/db16-1478","article-title":"Opioid receptor activation impairs hypoglycemic counterregulation in humans","volume":"66","author":"Carey","year":"2017","journal-title":"Diabetes"},{"issue":"6 Pt 1","key":"2025012110264103500_dgae479-B13","first-page":"E852","article-title":"Opiate blockade enhances hypoglycemic counterregulation in normal and insulin-dependent diabetic subjects","volume":"260","author":"Caprio","year":"1991","journal-title":"Am J Physiol"},{"issue":"9","key":"2025012110264103500_dgae479-B14","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1210\/jc.2009-0882","article-title":"Hypoglycemia-associated autonomic failure is prevented by opioid receptor blockade","volume":"94","author":"Leu","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012110264103500_dgae479-B15","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1210\/jc.2011-1723","article-title":"Opioid receptor blockade improves hypoglycemia-associated autonomic failure in type 1 diabetes mellitus","volume":"96","author":"Vele","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025012110264103500_dgae479-B16","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/dmrr.404","article-title":"Glucosensing neurons in the ventromedial hypothalamic nucleus (VMN) and hypoglycemia-associated autonomic failure (HAAF)","volume":"19","author":"Routh","year":"2003","journal-title":"Diabetes Metab Res Rev"},{"key":"2025012110264103500_dgae479-B17","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3389\/fphys.2018.00192","article-title":"Hypoglycemia: role of hypothalamic glucose-inhibited (GI) neurons in detection and correction","volume":"9","author":"Zhou","year":"2018","journal-title":"Front Physiol"},{"issue":"4","key":"2025012110264103500_dgae479-B18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1172\/JCI97696","article-title":"Hypoglycemia unawareness in type 1 diabetes suppresses brain responses to hypoglycemia","volume":"128","author":"Hwang","year":"2018","journal-title":"J Clin Invest"},{"issue":"1-2","key":"2025012110264103500_dgae479-B19","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0006-8993(83)90023-9","article-title":"Chronic naltrexone increases opiate binding in brain and produces supersensitivity to morphine in the locus coeruleus of the rat","volume":"289","author":"Bardo","year":"1983","journal-title":"Brain Res"},{"issue":"9","key":"2025012110264103500_dgae479-B20","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1210\/jc.2017-00477","article-title":"Hypothalamic glucose transport in humans during experimentally induced hypoglycemia-associated autonomic failure","volume":"102","author":"Seaquist","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012110264103500_dgae479-B21","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1210\/clinem\/dgaa539","article-title":"Plasma epinephrine contributes to the development of experimental hypoglycemia-associated autonomic failure","volume":"105","author":"Lontchi-Yimagou","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025012110264103500_dgae479-B22","doi-asserted-by":"crossref","first-page":"bvac046","DOI":"10.1210\/jendso\/bvac046","article-title":"Heterogeneity in epinephrine response to experimental hypoglycemia in type 1 diabetes and controls","volume":"6","author":"Zhang","year":"2022","journal-title":"J Endocr Soc"},{"key":"2025012110264103500_dgae479-B23","doi-asserted-by":"crossref","unstructured":"Aleksic S, Lontchi-Yimagou E, Mitchell WG, et al \u00a02024. Effects of intranasal naloxone on Hypoglycemia-Associated Autonomic Failure (HAAF) in susceptible individuals: supplementary materials. figshare. doi:10.6084\/m9.figshare.26014909.v1.","DOI":"10.1210\/clinem\/dgae479"},{"issue":"10","key":"2025012110264103500_dgae479-B24","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/jcph.759","article-title":"Pharmacokinetic properties and human use characteristics of an FDA-approved intranasal naloxone product for the treatment of opioid overdose","volume":"56","author":"Krieter","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2025012110264103500_dgae479-B25","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/add.14033","article-title":"Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: phase I healthy volunteer study","volume":"113","author":"McDonald","year":"2018","journal-title":"Addiction"},{"issue":"11","key":"2025012110264103500_dgae479-B26","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2337\/diab.42.11.1683","article-title":"Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM","volume":"42","author":"Fanelli","year":"1993","journal-title":"Diabetes"},{"issue":"2","key":"2025012110264103500_dgae479-B27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1210\/jc.2011-1391","article-title":"Magnitude of exercise-induced \u03b2-endorphin response is associated with subsequent development of altered hypoglycemia counterregulation","volume":"97","author":"Milman","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025012110264103500_dgae479-B28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2337\/diacare.17.3.183","article-title":"Effect of antecedent hypoglycemia on cognitive function and on glycemic thresholds for counterregulatory hormone secretion in healthy humans","volume":"17","author":"Mellman","year":"1994","journal-title":"Diabetes Care"},{"issue":"1","key":"2025012110264103500_dgae479-B29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2337\/db10-0326","article-title":"Naloxone, but not valsartan, preserves responses to hypoglycemia after antecedent hypoglycemia: role of metabolic reprogramming in counterregulatory failure","volume":"60","author":"Poplawski","year":"2011","journal-title":"Diabetes"},{"issue":"5","key":"2025012110264103500_dgae479-B30","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1111\/dom.12855","article-title":"Evaluation of the counter-regulatory responses to hypoglycaemia in patients with type 1 diabetes during opiate receptor blockade with naltrexone","volume":"19","author":"Naik","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2025012110264103500_dgae479-B31","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/j.jdiacomp.2015.08.004","article-title":"Naltrexone for treatment of impaired awareness of hypoglycemia in type 1 diabetes: a randomized clinical trial","volume":"29","author":"Moheet","year":"2015","journal-title":"J Diabetes Complications"},{"issue":"6","key":"2025012110264103500_dgae479-B32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat Neurosci"},{"issue":"1","key":"2025012110264103500_dgae479-B33","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1080\/10717544.2020.1837291","article-title":"Direct nose to brain delivery of small molecules: critical analysis of data from a standardized","volume":"27","author":"Dhuyvetter","year":"2020","journal-title":"Drug Deliv"},{"issue":"Pt 2","key":"2025012110264103500_dgae479-B34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1469-7793.1999.0431t.x","article-title":"Pre- and postsynaptic actions of opioid and orphan opioid agonists in the rat arcuate nucleus and ventromedial hypothalamus in vitro","volume":"517","author":"Emmerson","year":"1999","journal-title":"J Physiol"},{"issue":"4","key":"2025012110264103500_dgae479-B35","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.neuroscience.2008.01.033","article-title":"Presynaptic actions of opioid receptor agonists in ventromedial hypothalamic neurons in estrogen- and oil-treated female mice","volume":"152","author":"Devidze","year":"2008","journal-title":"Neuroscience"},{"issue":"3","key":"2025012110264103500_dgae479-B36","first-page":"1325","article-title":"Beta-endorphin inhibits hypoglycemia-induced gene expression of corticotropin-releasing factor in the rat hypothalamus","volume":"130","author":"Suda","year":"1992","journal-title":"Endocrinology"},{"issue":"6","key":"2025012110264103500_dgae479-B37","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.2337\/dc14-2319","article-title":"Selective insulin resistance in homeostatic and cognitive control brain areas in overweight and obese adults","volume":"38","author":"Kullmann","year":"2015","journal-title":"Diabetes Care"},{"issue":"3 Pt 1","key":"2025012110264103500_dgae479-B38","first-page":"E236","article-title":"Effect of opiate-receptor blockade on normoglycemic and hypoglycemic glucoregulation","volume":"250","author":"el-Tayeb","year":"1986","journal-title":"Am J Physiol"},{"issue":"2","key":"2025012110264103500_dgae479-B39","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2826.1991.tb00257.x","article-title":"Intrahypothalamic mu-, not delta- or kappa-opioid receptor activation causes growth hormone secretion","volume":"3","author":"Willoughby","year":"1991","journal-title":"J Neuroendocrinol"},{"issue":"2","key":"2025012110264103500_dgae479-B40","doi-asserted-by":"crossref","first-page":"774","DOI":"10.2527\/1991.692774x","article-title":"Changes in growth hormone and luteinizing hormone following acute or chronic administration of an opioid agonist, FK33\u2013824, in wethers","volume":"69","author":"Armstrong","year":"1991","journal-title":"J Anim Sci"},{"issue":"4","key":"2025012110264103500_dgae479-B41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.2527\/1993.7141004x","article-title":"A synthetic opioid peptide increases plasma growth hormone and prolactin in Holstein calves","volume":"71","author":"Johnson","year":"1993","journal-title":"J Anim Sci"},{"issue":"1","key":"2025012110264103500_dgae479-B42","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1055\/s-2007-978827","article-title":"Opioid-receptor blockade blunts growth hormone (GH) secretion induced by GH-releasing hormone in the human male","volume":"30","author":"Tomasi","year":"1998","journal-title":"Horm Metab Res"},{"issue":"7","key":"2025012110264103500_dgae479-B43","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1055\/s-2005-870230","article-title":"Effect of opiates on growth hormone secretion in acromegaly","volume":"37","author":"Bhansali","year":"2005","journal-title":"Horm Metab Res"},{"issue":"1","key":"2025012110264103500_dgae479-B44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1210\/er.2009-0009","article-title":"The effects of opioids and opioid analogs on animal and human endocrine systems","volume":"31","author":"Vuong","year":"2010","journal-title":"Endocr Rev"},{"issue":"9","key":"2025012110264103500_dgae479-B45","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0024-3205(80)90329-X","article-title":"Naloxone inhibits prolactin and growth hormone release induced by intracellular glucopenia in the rats","volume":"27","author":"Okajima","year":"1980","journal-title":"Life Sci"},{"issue":"3","key":"2025012110264103500_dgae479-B46","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1210\/jcem-50-3-597","article-title":"Failure of naloxone to influence plasma growth hormone, prolactin, and cortisol secretions induced by insulin hypoglycemia","volume":"50","author":"Wakabayashi","year":"1980","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025012110264103500_dgae479-B47","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/BF03350058","article-title":"Effects of naloxone on prolactin, growth hormone and cortisol response to insulin hypoglycemia in obese subjects","volume":"12","author":"Papalia","year":"1989","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"2025012110264103500_dgae479-B48","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2337\/diab.32.2.134","article-title":"Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion","volume":"32","author":"Bolli","year":"1983","journal-title":"Diabetes"},{"key":"2025012110264103500_dgae479-B49"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae479\/58623230\/dgae479.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/2\/462\/58623230\/dgae479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/2\/462\/58623230\/dgae479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T05:27:00Z","timestamp":1737437220000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/2\/462\/7716761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,19]]},"references-count":49,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,19]]},"published-print":{"date-parts":[[2025,1,21]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae479","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,7,19]]}}}